Clinical trial
Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy…
NCT00242424 · Seattle Children's Hospital, Other · Completed
Key facts
| NCT number | NCT00242424 |
|---|---|
| Title | Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age |
| Official title | Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2005-2006 Formulation) Among Healthy Children 6 to 12 Weeks of Age |
| Acronym | GRC28 |
| Lead sponsor | Seattle Children's Hospital, Other |
| Collaborators | Sanofi Pasteur, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Inactivated Influenza Vaccine |
| Intervention type | Biological |
| Interventions | 2005-2006 trivalent inactivated influenza vaccine |
| Enrollment | 1,375 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Oct 20, 2005 |
| Last update posted | Jan 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: